A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies

Tumour exosome integrins determine organotropic metastasis

(2015) Ayuko Hoshino et al.   NATURE

End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma

(2015) W. P. Mason   NEURO-ONCOLOGY

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

(2015) L. Burt Nabors et al.   NEURO-ONCOLOGY

Targeting of αv-Integrins in Stem/Progenitor Cells and Supportive Microenvironment Impairs Bone Metastasis in Human Prostate Cancer

(2015) Geertje van der Horst et al.   NEOPLASIA

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

Does cilengitide deserve another chance?

(2014) Marco Tucci et al.   LANCET ONCOLOGY

Integrin inhibition promotes atypical anoikis in glioma cells

(2014) M Silginer et al.   Cell Death & Disease

Integrin control of the transforming growth factor-β pathway in glioblastoma

(2013) Patrick Roth et al.   BRAIN

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

(2012) L. Burt Nabors et al.   CANCER

Abstract 1568: GLPG0187, a small molecule integrin antagonist, shows good safety and decrease in CTX levels in single ascending dose study

(2011) Giocondo Lorenzon et al.   CANCER RESEARCH

PP 87 Molecular imaging demonstrates GLPG0187, a small-molecule integrin antagonist, binds to RGD-integrin receptors in vivo and is efficacious in tumor and metastasis models

(2011) P. Pujuguet et al.   EUROPEAN JOURNAL OF CANCER

Integrins in Cell Migration

(2011) A. Huttenlocher et al.   Cold Spring Harbor Perspectives in Biology

GLPG0187 inhibits progression of established bone metastasis and achieves maximum efficacy when combined with standard-of-care metastatic breast cancer treatments

(2010) P. Clément-Lacroix et al.   BONE

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY